General Dermatology

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

Around 80% of clinical trials face enrollment delays, and for rare genodermatoses with small patient pools, AI-generated synthetic control arms may offer a practical path to adequately powered studies.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 AD SHORE trials for amlitelimab, the expansion of coverage for tirbanibulin, the start of a phase 2b/3 of brepocitinib for LPP, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Learn more about the in-depth topics covered in the March 2026 print issue of Dermatology Times.

Dermatology Times is recapping our exclusive expert interviews from the month of March.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

At AAD 2026, Maria-Angeliki Gkini, MD, PhD, shared guidance on diagnosing and managing topical steroid withdrawal syndrome.

Daniel C. Butler, MD, discusses adherence challenges, medication risks, and practical strategies to optimize dermatologic care in older adults.

This year’s AAD poster awards highlight studies advancing skin cancer prevention, inflammatory disease management, and complex dermatology care.

These leaders are shaping the future of dermatology through their clinical expertise, research, and educational presentations.

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Overall, the future of dermatology lies in integrating innovation with individualized, evidence-based, and patient-centered care.

Twin experts reveal how dermatology and dentistry team up for facial aesthetics, early lesion detection, and safer care—from lasers to oral screenings.